Home Tags COVAXIN
Dr Ella while delivering the award lecture, said there was a requirement to create an ecosystem where India should innovate and not copy from other countries and encourage start-ups
The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.
100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant
The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events
Mix and match of different vaccines is safe and elicits robust antibody response, revealed the study conducted by AIG Hospitals The first pilot study from India analyzing COVAXIN – COVISHEILD mixed doses
Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults......................
This first publication of the data shows COVAXIN has 93.4% efficacy against severe COVID-19 disease, 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of 25,798 participants..........................
Covaxin, developed in India by Bharat Biotech, gained emergency approval from the World Health Organization (WHO) and has already been cleared for use in 17 countries......................